��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title Elevated CSF P-tau181 and Total-tau and Reduced P-tau181/T-tau Ratio in Pre-Symptomatic Familial Alzheimer's Disease

Topic Aging and Dementia

Presentation(s) (-)

Poster/Presentation
Number 047

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
John M. Ringman, MD, FAAN (Keck School of Medicine of USC, Neurology Dept)	The institution of Dr. Ringman has received research support from Avid Pharmaceuticals. The institution of Dr. Ringman has received research support from AltaMed. The institution of Dr. Ringman has received research support from CurePSP.
Joash T. Lazarus, MD (Atlanta Neuroscience Institute)	Dr. Lazarus has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Lazarus has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers squib. Dr. Lazarus has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for USWM. Dr. Lazarus has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for arcadia. Dr. Lazarus has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for acorda. Dr. Lazarus has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine. Dr. Lazarus has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for allergan. The institution of Dr. Lazarus has received research support from Genentech.
William K. Seltzer, PhD	No disclosure on file
	No disclosure on file
Luis D. Medina, PhD (University of Houston)	The institution of Dr. Medina has received research support from National Institutes of Health. Dr. Medina has received personal compensation in the range of $500-$4,999 for serving as a Speaker with AbbVie. Dr. Medina has a non-compensated relationship as a Council Member with Alzheimer's Association that is relevant to AAN interests or activities.
	No disclosure on file
	No disclosure on file
Arousiak V. Maraian, MD	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jeffrey L. Cummings, MD, FAAN	Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.